Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by rfk67on Jul 16, 2007 11:30pm
492 Views
Post# 13098968

RE: date of purchase

RE: date of purchaseYou have the general idea ronrydell but the real credibility moment for a drug comes when phaseII data is avaliable. As you know water can pass phaseI, as can grape jelly for that matter, but that doesn't really tell you anything about the efficacy of the drug in question. While phaseI is obviously important it is often a formality as company's most often have enough relevant animal model data at this point to be pretty confident that it won't be toxic for humans. On another note I notice that the inside info., $60 buyout by February crowd is either gone, silent or talking about what is going to happen after phaseI (in one case their insiders have now morphed into "knowledgable posters" that they know). Shameless but then again when O&G guys show up on a biopharma type play with inside info. one would have to be rather naive to believe the hype.
Bullboard Posts